Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug;85(2):894-905.
doi: 10.1007/s12020-024-03793-5. Epub 2024 Apr 9.

Epidemiological analysis to identify predictors of X-linked hypophosphatemia (XLH) diagnosis in an Italian pediatric population: the EPIX project

Affiliations

Epidemiological analysis to identify predictors of X-linked hypophosphatemia (XLH) diagnosis in an Italian pediatric population: the EPIX project

Salvatore Crisafulli et al. Endocrine. 2024 Aug.

Abstract

Purpose: X-linked hypophosphatemia (XLH) is a rare multi-systemic disease characterized by low plasma phosphate levels. The aim of this study was to investigate the annual XLH prevalence and internally evaluate predictive algorithms' application performance for the early diagnosis of XLH.

Methods: The PediaNet database, containing data on more than 400,000 children aged up to 14 years, was used to identify a cohort of XLH patients, which were matched with up to 10 controls by date of birth and gender. The annual prevalence of XLH cases per 100,000 patients registered in PediaNet database was estimated. To identify possible predictors associated with XLH diagnosis, a logistic regression model and two machine learning algorithms were applied. Predictive analyses were separately carried out including patients with at least 1 or 2 years of database history in PediaNet.

Results: Among 431,021 patients registered in the PediaNet database between 2007-2020, a total of 12 cases were identified with a mean annual prevalence of 1.78 cases per 100,000 patients registered in PediaNet database. Overall, 8 cases and 60 matched controls were included in the analysis. The random forest algorithm achieved the highest area under the receiver operating characteristic curve (AUC) value both in the one-year prior ID (AUC = 0.99, 95% CI = 0.99-1.00) and the two-year prior ID (AUC = 1.00, 95% CI = 1.00-1.00) analysis. Overall, the XLH predictors selected by the three predictive methods were: the number of vitamin D prescriptions, the number of recorded diagnoses of acute respiratory infections, the number of prescriptions of antihistamine for systemic use, the number of prescriptions of X-ray of the lower limbs and pelvis and the number of allergology visits.

Conclusion: Findings showed that data-driven machine learning models may play a prominent role for the prediction of the diagnosis of rare diseases such as XLH.

Keywords: Epidemiology; Machine learning; Rare diseases; X-linked hypophosphatemia.

PubMed Disclaimer

Conflict of interest statement

G.T. has served in the past three years on advisory boards/seminars funded by SANOFI, Eli Lilly, AstraZeneca, Abbvie, Servier, Mylan, Gilead and Amgen; he was the scientific director of a Master program on pharmacovigilance, pharmacoepidemiology and real-world evidence which has received non-conditional grant from various pharmaceutical companies; he coordinated a pharmacoepidemiology team at the University of Messina until October 2020, which has received funding for conducting observational studies from various pharmaceutical companies (Boehringer Ingelheim, Daichii Sankyo, PTC Pharmaceuticals). He is also scientific coordinator of the academic spin-off “INSPIRE srl” which has received funding for conducting observational studies from contract research organizations (RTI Health Solutions, Pharmo Institute N.V.). All the above-mentioned activities are not related to the topic of the manuscript. Y.I. is the CEO of the academic spin-off “INSPIRE srl”, which has received funding for conducting observational studies from contract research organizations (RTI Health Solutions, Pharmo Institute N.V.) and from pharmaceutical Companies (Chiesi Italia, Kyowa Kirin s.r.l., Daiichi Sankyo Italia S.p.A.); D.L. is an employee at Medical Affairs of Kyowa Kirin. All the other authors have no conflict of interest to declare.

Figures

Fig. 1
Fig. 1
Flow-chart of cases and controls identified in PediaNet with at least one or two years of database history prior to the index date, respectively. ID Index Date, XLH X-linked hypophosphataemia
Fig. 2
Fig. 2
Plot of the annual X-linked hypophosphataemia prevalence per 100,000 individuals in the period 2007–2020. The dashed blue line represents the average annual prevalence
Fig. 3
Fig. 3
Performance of models for X-linked hypophosphatemia diagnosis prediction, both within 1 year and 2 years prior to the index date. A Area under the curve of the developed algorithms; B sensitivity of the developed algorithms; C specificity of the developed algorithms; D F-score of the developed algorithms; E positive predictive value of the developed algorithms; F negative predictive value of the developed algorithms; G Youden Index of the developed algorithms.

References

    1. The HYP Consortium, A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. Nat. Genet. 11, 130–136 (1995) 10.1038/ng1095-130 - DOI - PubMed
    1. Hereditary hypophosphatemic rickets. Genetics Home Reference. (2010). http://ghr.nlm.nih.gov/condition/hereditary-hypophosphatemic-rickets (accessed 25 July 2023)
    1. J.S. Steven, K.D. Marc. Hereditary Hypophosphatemic Rickets and Tumor-Induced Osteomalacia. UpToDate. (2023). https://www.uptodate.com/contents/hereditary-hypophosphatemic-rickets-an... (accessed 25 July 2023)
    1. S.S. Beck-Nielsen, B. Brock-Jacobsen, J. Gram et al. Incidence and prevalence of nutritional and hereditary rickets in southern Denmark. Eur. J. Endocrinol. 160, 491–497 (2009) 10.1530/EJE-08-0818 - DOI - PubMed
    1. S. Rafaelsen, S. Johansson, H. Ræder et al. Hereditary hypophosphatemia in Norway: a retrospective population-based study of genotypes, phenotypes, and treatment complications. Eur. J. Endocrinol. 174, 125–136 (2016) 10.1530/EJE-15-0515 - DOI - PMC - PubMed

LinkOut - more resources